Medifast Q2 2025 Earnings Report

Medifast EPS Results

• Actual EPS: $0.04
• Consensus EPS: -$0.22
• Beat/Miss: Beat by +$0.26
• One Year Ago EPS: N/A

Medifast Revenue Results

• Actual Revenue: $105.56 million
• Expected Revenue: $96.10 million
• Beat/Miss: Beat by +$9.46 million
• YoY Revenue Growth: N/A

Medifast Announcement Details

• Quarter: Q2 2025
• Date: 8/4/2025
• Time: After Market Closes
• Conference Call Date: Monday, August 4, 2025
• Conference Call Time: 4:30PM ET

Medifast (NYSE:MED), Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

Medifast Q2 2025 Earnings Call Transcript

Key Takeaways

• Negative Sentiment: Medifast reported Q2 revenue of $105.6 million, down 37.4% year-over-year with active coaches declining 32.7%, and Q3 guidance of $70 million–$90 million and $0 to –$0.60 EPS signals ongoing challenges.
• Positive Sentiment: The new Premier Plus auto-ship program simplifies discounts and shipping for over 90% of clients, aiming to improve retention and make the value proposition clearer for both clients and coaches.
• Positive Sentiment: Introduction of the EDGE coach incentives and enhanced digital app functionality is designed to boost coach productivity, streamline reporting, and support business building efforts.
• Positive Sentiment: Clinical data shows OPTAVIA’s programs achieve 98% lean mass retention during weight loss versus up to 40% loss with GLP-1 drugs alone, reinforcing Medifast’s value in long-term metabolic health.
• Positive Sentiment: Medifast ended Q2 with $162.7 million in cash, no debt, and a strong balance sheet to fund strategic initiatives and coach-focused transformations.

Presentation

[Operator]

Greetings, and welcome to the Medifast Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce you to your host, Steven Zinker, VP, Investor Relations. Thank you, Steven. You may begin.

[Steven Zenker, Vice President of Investor Relations at Medifast]

Good afternoon, and welcome to Medifast's Second Quarter twenty twenty five Earnings Conference Call. On the call with me today are Dan Chard, Chairman and Chief Executive Officer and Jim Maloney, Chief Financial Officer. By now, everyone should have access to the earnings release for the second quarter ended 06/30/2025 that went out this afternoon at approximately 04:05PM Eastern Time. If you have not received the release, it is available on the Investor Relations portion of Medifast website at www.medifastinc.com. This call is being webcast and a replay will also be available on the company's website.

[Steven Zenker, Vice President of Investor Relations at Medifast]

Before we begin, we would like to remind everyone that today's prepared remarks contain forward looking statements and management may make additional forward looking statements in response to your questions. The words believe, expect, anticipate and other similar expressions generally identify forward looking statements. These statements do not guarantee future performance and therefore under reliance should not be placed on them. Actual results could differ materially from those projected in any forward looking statements. All of the forward looking statements contained herein speak only as of the date of this call.

[Steven Zenker, Vice President of Investor Relations at Medifast]

Medifast assumes no obligation to update any forward looking statements that may be made in today's release or call. Now I would like to turn the call over to Medifast's Chairman and Chief Executive Officer, Dan Chard.

[Dan Chard, Chairman & CEO at Medifast]

Thank you, Steve, and good afternoon, everyone. We're glad to be here with you today to share some updates on our progress over the 2025. We continue to work diligently to transform our business and capitalize on the significant opportunities in helping people achieve their health goals, especially as it relates to weight loss and optimal metabolic health. We are also keenly focused on coach productivity and coach growth through targeted initiatives that aim to enhance our offer, support coach business success, and help us maintain a strong balance sheet. The rapid adoption of GLP-one medications has brought unprecedented attention to the issue of obesity and the critical role that weight plays in overall health.

[Dan Chard, Chairman & CEO at Medifast]

GLP-1s can be a powerful appetite suppressant, helping to turn down the food noise, but studies are in agreement that medication on its own does not help users develop the lifestyle changes necessary to achieve and sustain optimal metabolic health, which includes preserving lean mass. Research indicates that without adopting sustainable lifestyle changes, individuals who lose weight using GLP-one medications often experience loss of lean mass, which includes muscle, of up to 40% of total weight lost, and tend to regain most of the weight back within a year after discontinuing use of the drug. This is where our programs are built to make a difference. Each program is developed to guide individuals in adopting and maintaining healthy habits that not only promote weight loss, but also maximize fat burn while preserving lean mass. In fact, a recent study of randomized clinical trial data showed that clients using the OPTAVIA five and one plan maintained 98% of lean mass during weight loss.

[Dan Chard, Chairman & CEO at Medifast]

This is due to a holistic nutrition and lifestyle approach to ensure lean mass support during the active weight loss phase and through the critical maintenance phase that follows. We believe that healthy habits are essential to long term health, and with research showing that up to seventy four percent of people stop GLP-one medications for weight loss within a year or less of starting them, there's a growing need for an effective long term solution that helps people maintain their weight loss progress, whether or not they have used medications as part of their efforts to improve their health. The science that supports our clinically studied programs is rooted in three key design elements. First, fostering sustainable change through coach and community support. Second, targeting and optimizing fat burn and lean muscle maintenance.

[Dan Chard, Chairman & CEO at Medifast]

And third, supporting gut health. As science evolves, so do we, meeting people where they are and helping them navigate life's changes and challenges. While the core of our program continues to be very relevant, we are in the midst of a comprehensive evolution of our company to maximize the business opportunity for our coaches while offering tailored solutions to our clients. We cater to individuals looking to lose weight and achieve optimal metabolic health, whether they are currently using GLP-one medications, transitioning off of them, or not using medications at all. Our focus is on helping all clients protect their lean body mass and adopt a healthy lifestyle to achieve their best health outcomes.

[Dan Chard, Chairman & CEO at Medifast]

We're now entering into the next phase of our evolution as we leverage science and clinical research to extend the impact of our flagship five in-one program and product line to address the growing challenges associated with poor metabolic health. Ninety three percent of U. S. Adults are metabolically unhealthy, which leads to weight gain, low energy, and higher risk of chronic illness. This is a growing health challenge that, based on recent study data, we believe OPTAVIA will be in a position to address.

[Dan Chard, Chairman & CEO at Medifast]

We'll have more to say about this and the specifics later this year. At the heart of our approach is leveraging important science breakthroughs that we believe will enhance our performance in areas of strength while also addressing important new areas of performance in our focus to deliver optimal metabolic health and well-being for our clients. As always, our programs are supported by a personalized experience powered by dedicated coaches and a supportive community, an approach designed to inspire meaningful, lasting transformation. Coaches are a central driver of the long term success of our program. Many of our coaches have experienced their own transformation through the program and are uniquely equipped to help others on their path to optimal metabolic health.

[Dan Chard, Chairman & CEO at Medifast]

Twenty three percent of OPTAVIA Coaches have personal experience in using GLP-one drugs in their own health journey, and now sixty percent have coached a client who has used GLP-one medication. Their experience, combined with a simple and actionable plan, is what makes our program distinctive and effective, helping clients at every stage, from weight loss to optimal metabolic health. We are a coach first business. Our focus is squarely on energizing and upgrading the tools that help coaches build their businesses and maximize their impact on clients. We are doing this in an integrated phased way, starting with broadening our port product portfolio through the introduction of the active and ascend lines, and now expanding into enhancements to our mobile app and web platform.

[Dan Chard, Chairman & CEO at Medifast]

These changes are designed to deliver actionable insights, simplify coach reporting, and streamline both our coach economics and product pricing models. In July, we launched a new pricing and incentive structure for our auto ship clients, who represent over 90% of our client base. This new structure, named Premier Plus, integrates discounts beyond a client's first order and replaces a more complex system of loyalty credits with straightforward upfront savings, simplifying the value proposition for clients and giving coaches a more consistently priced client offer than previously available. From a client perspective, the new pricing is simpler and easier to understand. They get discounts on every order, provided they meet a minimum order size.

[Dan Chard, Chairman & CEO at Medifast]

And clients pay one fixed price for shipping, regardless of order size. These improvements help make our program more compelling to prospective clients and easier to explain for coaches. The coaches should benefit by making it easier to attract and retain clients, while also making the coach compensation plan payout more predictable and easy to understand, as no adjustments have to be made for promotions or loyalty credits. This also makes it easier coaches to recruit new coaches and help those new coaches grow their businesses. Going forward, we expect that our use of promotions will be limited, likely resulting in more consistent client demand across the year.

[Dan Chard, Chairman & CEO at Medifast]

We also believe this new approach will encourage clients to stay on the program longer. Additionally, because our model works best when our coaches are aligned and focused on the same core client support and business building behaviors, we introduced a program called EDGE in the second quarter, which features a set of integrated coach incentives, best practices, and recognition tools to reinforce the behaviors that drive success and business building. It's designed to be accessible for both new and experienced coaches, providing a clear and motivating structure for growth and alignment to help them turn part time work into a thriving business. The changes the EDGE program introduces are intended to simplify onboarding for coaches to bring on new clients, create faster and more meaningful early wins, and provide a clear pathway for advancement and compensation growth. We're complementing this with improved leadership development training, empowering coaches to build thriving businesses.

[Dan Chard, Chairman & CEO at Medifast]

In addition, new digital app functionality provides more robust data for coaches to allow them to track both their own business building progress and their clients' progress in their optimal metabolic health journey. All of this enables a greater focus on personalized client service and provides better insights into how coaches can best build their businesses. Now turning to quarterly results. Revenue and EPS came in above our guidance. The total number of coaches during the quarter totaled 22,800, down 33% from 2024.

[Dan Chard, Chairman & CEO at Medifast]

Year over year coach productivity declined 7% versus 2024, in part reflecting the timing of promotions. In this year's second quarter, we did not utilize any promotions. Although the total number of coaches and the average revenue per coach declined compared to the same quarter last year, average revenue per coach increased sequentially for the second consecutive quarter. New coach acquisition growth in the second quarter was down compared to the prior year, again reflecting the absence of promotions compared with last year's second quarter. We continue to see strong productivity among new coaches at levels we've historically seen during growth periods in the past, and we expect that trend to continue into next year.

[Dan Chard, Chairman & CEO at Medifast]

While our transformation continues to evolve, we are taking meaningful steps to position the company for future success in the years ahead. Reigniting the Coach Growth Engine is a top priority, and we have initiatives underway on multiple fronts to support this. Now I will turn it over to Jim to go over the quarter and our projections for the next quarter.

[Jim Maloney, CFO at Medifast]

Thank you, Dan. Good afternoon, everyone. As Dan mentioned earlier, second quarter twenty twenty five results for both revenue and EPS were above our guidance ranges. Revenue for the second quarter was $105,600,000 a decrease of 37.4% versus the year earlier period, primarily due to a decrease in the number of active earning OPTAVIA Coaches. We ended the quarter with approximately 22,800 active earning OPTAVIA Coaches, a decrease of 32.7% from the 2024.

[Jim Maloney, CFO at Medifast]

Average revenue per active earning OPTAVIA Coach for the second quarter was $4,630 a year over year decrease of 6.9%, primarily driven by continued pressure on client acquisition and timing differences in promotional activity. In 2024, promotional activity occurred in late Q1 into early Q2, while in 2025, promotional activity only occurred in Q1. Coach productivity was actually up sequentially for the second consecutive quarter and the percentage decline improved year over year from Q2 twenty twenty four, which decreased 10.9%. Gross profit decreased 37.9% year over year to $76,600,000 driven by lower sales volumes. Gross profit margin for the current quarter was 72.6%, which decreased 60 basis points compared to the year earlier period.

[Jim Maloney, CFO at Medifast]

SG and A expense was down 40.8% year over year to $77,700,000 primarily due to $24,300,000 decrease in OPTAVIA Coach compensation on fewer active earning coaches and lower volumes. Additionally, the company incurred costs in the 2024 that did not recur in the 2025, including $12,500,000 for supply chain optimization, dollars 3,000,000 for cancellation of OPTAVIA conventions in the future years, and 2,000,000 for the company's collaboration with LifeMD. SG and A as a percentage of revenue decreased four thirty basis points, primarily due to approximately seven forty basis points for supply chain optimization initiatives, 180 basis point for cancellation of OPTAVIA convention incurred in the 2024 that did not recur in the 2025, partially offset by four forty basis points attributable to the loss of leverage on fixed cost due to lower sales volumes. Loss from operations was $1,100,000 in the 2025, an improvement of $6,800,000 versus the year earlier period as the decline in gross profit was more than offset by lower SG and A. As a percentage of revenue, loss from operations was 1% in the second quarter in an increase of three seventy basis points compared to the year earlier period.

[Jim Maloney, CFO at Medifast]

Other income increased 242.1% year over year to $3,900,000 primarily due to a gain on investment in LifeMD common stock. The company's gain on investment in LifeMD common stock for the 2025 was $2,600,000 compared to a loss of investment of $4,200,000 for the corresponding period in 2024. During the quarter, we liquidated our position in LifeMD common stock. We initially invested in LifeMD to kick start our collaboration and while we continue to offer our clients access to LifeMD clinicians, we do not need to hold the common stock investment in LifeMD to sustain this strategy. We never viewed the investment in LifeMD common stock as a long term investment.

[Jim Maloney, CFO at Medifast]

Our goal with all our investments is to favor ones that protect our principle and meet certain duration and risk parameters. The effective tax rate was 13.7% for the 2025 compared to 23.4% in the prior year period. The change in the effective tax rate for the three months ended 06/30/2025, was primarily driven by the increase in the limitation for executive compensation, which was magnified by the near breakeven pretax position in the current year. Net income in the 2025 was $2,500,000 or $0.22 per diluted share compared to a net loss of $8,200,000 or $0.75 per share in the year earlier period. Importantly, our financial position remains strong with $162,700,000 in cash and cash equivalents and no interest bearing debt as of 06/30/2025.

[Jim Maloney, CFO at Medifast]

Now I will turn to guidance. We are expecting third quarter revenue to range from 70,000,000 to $90,000,000 and earnings per share for the quarter to range from $0.00 to a loss of $0.60 Dan mentioned earlier that we have begun rolling out our new Premier Plus auto ship program in the third quarter. I did want to mention that we do not expect to see any appreciable difference in our margins going forward from the adjustments, as any impact from the pricing changes is expected to be offset by other incremental actions taken under the program. With that, let me turn the call to the operator for questions.

[Operator]

Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue.

[Operator]

For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star key. Thank you. Our first question comes from the line of Jim Salera with Stephens. Please proceed.

[Jim Salera, Research Analyst at Stephens Inc]

Hey, Jim. Good afternoon. Thanks for taking our question. I wanted to start off maybe just with some thoughts around the coach composition. Just as the landscape changes in the selling format, the value proposition for the OPTAVIA portfolio, more aligns closely with GLP-one.

[Jim Salera, Research Analyst at Stephens Inc]

Have you seen a significant change in your composition of coaches and kind of a different group of coaches replacing some of older ones that are more focused on GLP-one as the messaging? Or do you have kind of a split between legacy coaches that still focus on the traditional OPTAVIA messaging and then a new segment of coaches that focus on the more GLP-one line? Just any thoughts on kind of how the coaches are adapting to this changing landscape?

[Dan Chard, Chairman & CEO at Medifast]

Yeah, Jim, let me take that one. Also I'll introduce, Nick Johnson who has been on this call before, who's our Chief Field Operations Officer. I'm make a couple of comments and then ask him to address that point specifically, because I think one of the announcements we made drives towards an important part of how we're working with our coaches and how we're changing the business to help operate in this new environment. So you heard us talk a little bit about the new study on clinical research that we're increasing our focus on metabolic health because it's an upstream driver of many of the age related health conditions, including overweight and obesity. So this is an important move for us, partly because it addresses something that affects over ninety percent of Americans who are experiencing some kind of metabolic dysfunction.

[Dan Chard, Chairman & CEO at Medifast]

So when metabolic health is out of balance, it can trigger a cascade of challenges that millions of adults face today. It's an important thing because it's tied also to one of the things that is becoming more challenged in an environment that has a growing number of people who are using GLP-one drugs. We now have sixty percent of our coaches who are supporting at least one client who has used a GLP-one drug, and roughly twenty three percent of our client base also reflects people who have either used or are using GLP-one drugs. But most importantly, and then I'll turn it over to Nick to ask the question that, you asked, is that, as we go forward we'll be announcing some additional findings related to that new research to further reinforce this direction that will affect both product and the way our coaches approach clients in terms of reversing the impact of metabolic dysfunction. But I'll turn it to Nick to answer the specific question that you asked. Nick?

[Nicholas Johnson, Chief Field Operations Officer at Medifast]

Thanks, Dan. Thanks, Jim, for the question. Yeah, important one. I mean, productivity for our new coaches is important because this leads to the creation of the next generation of leaders and ultimately reigniting the flywheel of our business. So we've done a lot to focus specifically on supporting those folks over the last couple of quarters.

[Nicholas Johnson, Chief Field Operations Officer at Medifast]

Important to note, I mean, this kind of is obvious, but coach leaders have evolved their training to the new environment. So new coaches only know a world with GLP ones in them, but they're very familiar with it. Coach leadership talks about it, trains to it, understands them and understands what they do and do not do, understands where they fall short in the realm of metabolic health specifically around some of those outages that Dan alluded to that we'd be talking about more. The training specifically includes those who are on GLP-one currently and also those who are coming off of GLP-one. How do they transition?

[Nicholas Johnson, Chief Field Operations Officer at Medifast]

So half of our coaches have supported someone on GLP-one medication. And like Dan said earlier, twenty five percent of coaches have used a GLP-one medication themselves. So we see that transition happening.

[Jim Salera, Research Analyst at Stephens Inc]

Great. And if I can ask a follow-up just on ASCEND. In the past, you you guys have talked about that as being particularly targeted towards the kind of GLP-one use case, pairing Ascend with somebody who's utilizing GLP-one drugs. Just give us an update on if you're able to share Ascend sales as a percentage of total or just what you're seeing there in terms of engagement and how that's been rolling out?

[Dan Chard, Chairman & CEO at Medifast]

Yeah, it continues to meet expectations. The product as it was developed, as you pointed out, was to perform two functions. One was to support clients who are using a GLP-one drug, and the other very important role is to help those who are transitioning off the five and one program into a maintenance phase. So it supports both of those roles. What we're seeing with our coaches and their clients is there's a lot of success in actually having clients use the five and one program while they're on a GLP-one regimen, and then transitioning to send later on.

[Dan Chard, Chairman & CEO at Medifast]

And that's true largely because the five and one provides a little bit more protein and overall calories at a time when GLP-one clients need to have support in maintaining that lean body mass. That clinical research that I mentioned earlier is related to that critical number. But overall, we see both the ASCEND line and its continued performance as well as the ACTIVE line, which is tied to clients who are exercising and need to maintain muscle as critical parts to our overall programs.

[Jim Salera, Research Analyst at Stephens Inc]

Great. And then maybe just one last one. I know in the past we tested some company supported marketing outside of the traditional coach led client acquisition. Then we part that back a little bit. Just any thoughts on how company supported marketing is going to play a hand in driving consumer engagement going forward?

[Dan Chard, Chairman & CEO at Medifast]

Yeah, this has been an important part of, what we've been doing. What we found is, those programs are highly effective at bringing back customers or clients who had been on the OPTAVIA program before. But we've found consistently that our coaches sharing their own personal messages is much more effective in bringing on new clients. It's also far more efficient for the company. So while we'll continue to strategically use advertising dollars largely to affect and influence search engine management, search engine optimization, we will continue to look to our coaches to share their personal stories of health transformation as we go forward in the future and have a more pared back budget related to company led acquisition.

[Jim Salera, Research Analyst at Stephens Inc]

Great. I appreciate the detail. I'll hop back in the queue.

[Operator]

Thank you. There are no further questions at this time. I'd like to pass the call back over to Dan Chard for any closing remarks.

[Dan Chard, Chairman & CEO at Medifast]

I'd like to thank everyone for your time today. This is an important moment for our business as we continue to transform, to meet the pressing needs of today's health and wellness landscape. With ninety three percent of adults facing some form of metabolic dysfunction, the opportunity to help millions of people protect their health and sustain their weight loss has never been greater. We're building this business for the long term with a science backed approach, a community of experienced coaches, and an offering that is designed to meet clients wherever they are in their journey. We'll be participating conferences this fall, including the Canaccord Genuity Annual Growth Conference on August 13.

[Dan Chard, Chairman & CEO at Medifast]

We look forward to continuing the conversation. Thanks again and we appreciate your continued interest in Medifest.

[Operator]

This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.

Participants

Executives

• Steven Zenker, Vice President of Investor Relations
• Dan Chard, Chairman & CEO
• Jim Maloney, CFO
• Nicholas Johnson, Chief Field Operations Officer

Analysts

• Jim Salera, Research Analyst at Stephens Inc